Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (107)
  2. Journal Article (86)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (202)
  2. Department of Medicine (202)
  3. Solid Tumor Oncology Division (202)
  4. GSK Faculty (57)
  5. Survivorship Research (44)
  6. Epidemiology and Biostatistics (41)

More Groups

People
  1. Shanu Modi (34)
  2. Sarat Chandarlapaty (27)
  3. Clifford Hudis (24)
  4. Pedram Razavi (22)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (8)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (53)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (9)
  5. European Journal of Cancer (5)
  6. Oncology Research and Treatment (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (56)
  2. American Association for Cancer Research (46)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (202)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ia/b study of giredestrant ± palbociclib and ± luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; Bellet, M.; Turner, N. C.; Loi, S.; Bardia, A.; Boni, V.; Sohn, J.; Neilan, T. G.; Villanueva-Vázquez, R.; Kabos, P.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Review

    Jhaveri, K.; Marmé, F.
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Tesch, H.; Tolaney, S.; Bardia, A.; Marmé, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tréedan, O.; Ciruelos, E.; Dalenc, F.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Meeting Abstract

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-advanced breast cancer (aBC): Results from the phase Ia/b EMBER
    Meeting Abstract

    Jhaveri, K.; Jeselsohn, R.; Ma, C. X.; Lim, E.; Yonemori, K.; Hamilton, E. P.; Harnden, K.; Im, S. A.; Beck, T.; Sammons, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Molecularly targeted therapies for triple negative breast cancer: History, advances, and future directions
    Review

    Mai, N.; Abuhadra, N.; Jhaveri, K.
    Clinical Breast Cancer (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer
    Journal Article

    Jhaveri, K.; O’Shaughnessy, J.; Fasching, P. A.; Tolaney, S. M.; Yardley, D. A.; Sharma, V. K.; Biswas, C.; Thuerigen, A.; Pathak, P.; Rugo, H. S.
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial
    Journal Article

    Rugo, H S.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: Outcomes and biomarker analysis from the SUMMIT trial
    Journal Article

    Jhaveri, K.; Eli, L. D.; Wildiers, H.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J.; Yang, E. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)
    Meeting Abstract

    Mayer, E. L.; Tolaney, S. M.; Brufsky, A.; Gradishar, W. J.; Jhaveri, K. L.; Martin, M.; Moscetti, L.; Schneeweiss, A.; Vidal, G. A.; Cortazar, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save